Visit https://www.peervoice.com/VZU860 to view the entire programme with slides. After completing “Prevention and Management of Cardiovascular Adverse Events in Multiple Myeloma: Safe and Appropriate Use of Proteasome Inhibitors”, participants will be able to: Describe the cardiovascular adverse events that have been associated with use of proteasome inhibitors for treatment of multiple myeloma; Develop strategies to prevent and manage cardiovascular adverse events in patients with multiple myeloma.